BeiGene, Ltd. (ONC)vsRoivant Sciences Ltd (ROIV)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
ROIV
Roivant Sciences Ltd
$27.36
+1.82%
HEALTHCARE · Cap: $19.23B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 40043% more annual revenue ($5.34B vs $13.31M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
ROIV
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for ROIV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% margin — thin
ROE of -19.1% — below average capital efficiency
Revenue declined 77.8%
Earnings declined 96.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : ROIV
The strongest argument for ROIV centers on Debt/Equity, Altman Z-Score.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : ROIV
The primary concerns for ROIV are Profit Margin, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while ROIV is a value play — different risk/reward profiles.
ROIV carries more volatility with a beta of 1.21 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 24/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Roivant Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming the way therapies are developed and commercialized, utilizing a distinctive model that leverages proprietary technologies. With a diverse pipeline addressing critical unmet needs in neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process, thereby reducing time and costs associated with bringing new therapies to market. The company's strong leadership team and strategic partnerships further enhance its potential to disrupt the healthcare landscape, creating significant value for investors while improving patient outcomes.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?